Akebia Therapeutics (AKBA) Non-Current Deffered Revenue (2015 - 2024)

Akebia Therapeutics (AKBA) has reported Non-Current Deffered Revenue for 10 consecutive years, with $43.3 million the latest figure, recorded in Q1 2024.

• In Q1 2024, Non-Current Deffered Revenue changed 0.0% year-over-year to $43.3 million; the TTM figure through Mar 2024 stood at $43.3 million (changed 0.0% YoY), while the FY2023 annual figure was $43.3 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue held at $43.3 million in Q1 2024 per AKBA's latest filing, from $43.3 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $65.4 million in Q1 2022 and bottomed at $16.6 million in Q2 2021.
• Historically, Non-Current Deffered Revenue has averaged $37.3 million across 5 years, with a median of $43.3 million in 2022.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue slumped 54.91% — and 2022, when it jumped 238.65%.
• Akebia Therapeutics' Non-Current Deffered Revenue stood at $25.3 million in 2020, then retreated by 15.27% to $21.5 million in 2021, then jumped by 101.62% to $43.3 million in 2022, then changed by 0.0% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024.
• Business Quant data shows AKBA's Non-Current Deffered Revenue at $43.3 million in Q1 2024, $43.3 million in Q4 2023, and $43.3 million in Q3 2023.